technique	gene	disease	oncotree_term	oncotree_code	context	therapy_name	therapy_strategy	therapy_type	therapy_sensitivity	therapy_resistance	favorable_prognosis	predictive_implication	description	preferred_assertion	source_type	citation	url	doi	pmid	nct	last_updated
shRNA	ATM	Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD	Olaparib	PARP inhibition	Targeted therapy	1			Preclinical	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.		Journal	"Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196."	https://doi.org/10.1016/j.tranon.2017.01.007	10.1016/j.tranon.2017.01.007	28182994		8/15/19
CRISPR-Cas9	B2M	Melanoma	Melanoma	MEL							0	Preclinical	Loss of antigen presentation via B2M loss of function mutations results in increased survival of cancer cells in the presence of tumor infiltrating lymphocytes. 		Journal	"Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy Nature. 2017; 548(7669):537-542."	https://doi.org/10.1038/nature23477	10.1038/nature23477	28783722		4/16/19
shRNA	CDK12	Ovarian Cancer	"Ovarian Cancer, Other"	OOVC		Olaparib	PARP inhibition	Targeted therapy	1			Preclinical	"shRNA knockout in ovarian cancer suggests suggests sensitivity to PARP1/2 inhibition, specifically olaparib."		Journal	"Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014;74(1):287-97."	https://doi.org/10.1158/0008-5472.CAN-13-2541	10.1158/0008-5472.CAN-13-2541	24240700		11/3/17
siRNA	CDK12	Ovarian Cancer	"Ovarian Cancer, Other"	OOVC		Veliparib	PARP inhibition	Targeted therapy	1			Preclinical	"siRNA knockout, ""gene depletion"", of CDK12 shows sensitivity to PARP inhibitor veliparib in ovarian cancer cell lines."		Journal	"Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem. 2014;289(13):9247-53."	https://doi.org/10.1074/jbc.M114.551143	10.1074/jbc.M114.551143	24554720		11/3/17
shRNA	CPT1A	Melanoma	Melanoma	MEL							1	Preclinical	"CPT1A is involved in fatty acid oxidation, a key component of some tumor's metabolic processes. CPT1A knockdown in some melanoma BRAF V600E cell lines resulted in decreased proliferation and tumorigenesis."		Journal	"Sung GJ, Choi HK, Kwak S, et al. Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation. Int J Biochem Cell Biol. 2016;81(Pt A):76-81."	https://doi.org/10.1016/j.biocel.2016.10.019	10.1016/j.biocel.2016.10.019	27793752		11/3/17
shRNA	RAD17	Breast Cancer	Invasive Breast Carcinoma	BRCA		Veliparib	PARP inhibition	Targeted therapy	1			Preclinical	"RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to ABT-888, Veliparib (PARP inhibitor). If RAD50 is also knocked out, a further increase in sensitivity is observed."		Journal	"Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133(3):865-80."	https://doi.org/10.1007/s10549-011-1846-y	10.1007/s10549-011-1846-y	22048815		11/3/17
shRNA	RAD17	Breast Cancer	Invasive Breast Carcinoma	BRCA		Carboplatin	Platinum-based chemotherapy	Chemotherapy	1			Preclinical	RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to carboplatin. A further increase in sensitivity occurred when knocked down with RAD50.		Journal	"Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133(3):865-80."	https://doi.org/10.1007/s10549-011-1846-y	10.1007/s10549-011-1846-y	22048815		11/3/17
shRNA	RAD50	Breast Cancer	Invasive Breast Carcinoma	BRCA		Carboplatin	Platinum-based chemotherapy	Chemotherapy		1		Preclinical	RNAi knockdown of RAD50 in the HME-CC breast cancer cell line resulted in increased resistance to carboplatin.		Journal	"Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133(3):865-80."	https://doi.org/10.1007/s10549-011-1846-y	10.1007/s10549-011-1846-y	22048815		11/3/17
CRISPR-Cas9	TAP2	Melanoma	Melanoma	MEL							0	Preclinical	Loss of antigen presentation via TAP2 loss of function mutations results in increased survival of cancer cells in the presence of tumor infiltrating lymphocytes. 		Journal	"Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy Nature. 2017; 548(7669):537-542."	https://doi.org/10.1038/nature23477	10.1038/nature23477	28783722		4/16/19